Robert Stein

Dr. Robert Stein has over 35 years of experience and accomplishments in the pharmaceutical and biotech industry. Over the course of his career, Bob has played a significant role in the discovery and development of eight marketed drugs, including Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta®, & Eliquis®. He currently is an advisor to Agenus, Inc’s global research and development efforts. Prior to serving as Agenus’ {resident of R&D, he held a number of progressively responsible senior management positions including Head of Pharmacology for Merck & Co., CSO & SVP of Research for Ligand Pharmaceuticals, EVP of Research & Preclinical Development for Dupont Merck, President and CSO for Incyte Pharmaceuticals, President of Roche Palo Alto, and CEO of KineMed.

Bob spent the early part of his career at Merck, Sharp and Dohme Research Laboratories. He holds an MD and a PhD in Physiology & Pharmacology from Duke University.